EU regulator recommends approval to expand Sogroya label
Novo Nordisk said the European Medicines Agency recommended approval of its Sogroya growth-hormone treatment for children with unexplained shortness, expanding the medicine’s current label.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.